Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine

Clinical and Diagnostic Laboratory Immunology

Volumn 4, Issue 3, 1997, Pages 302-308

  Lambert, John S ^a,b   Viscidi, Raphael ^b   Walker, Mary Clare ^c   Clayman, Barbara ^b   Winget, Marcy ^b   Wolff, Mark ^d   Schwartz, David H ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; VIRUS GLYCOPROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SEMINAL PLASMA; SERUM; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION;

EID: 0030979592     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.4.3.302-308.1997     Document Type: Article

References (27)

1. Archibald, D. W., C. A. Hebert, D. Sun, and C. O. Tacket. 1990. Salivary antibodies to human immunodeficiency virus type I in a phase I AIDS vaccine trial. J. Acquired Immune Defic. Syndr. 36:35-11.
2. Archibald, D. W., C. E. Barr, J. P. Torosian, M. F. McLane, and M. Essex. 1984. Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-relatcd complex. J. Infect. Dis. 155:793-796.
3. Archibald, D. W., D. J. Witt, D. E. Craven, M. W. Vogt, M. S. Hirsch, and M. Essex. 1987. Antibodies to human immunodeficiency virus in cervical secrelions from women at risk for AIDS. J. Infect. Dis. 156:240-241.
4. Artenstein, A. W., T. C. VanCott, K. V. Sitz, M. L. Robb, K. F. Wagner, S. C. D. Veit, A. F. Rogers, R. P. Garner, J. W. Byron, P. R. Burnett, and D. L. Birx. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J. Infect. Dis., in press.
5. Barrett, N. A., A. Mitterer, W. Mundt, J. Eibl, M. Eibl, R. C. Gallo, B. Moss, and F. Dorner. 1989. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res. Hum. Retroviruses 5:159-171.
6. Belec, L., A. J. Georges, G. Steenman, and P. M. V. Martin. 1989. Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women. J. Infect. Dis. 160:385-391.
7. Belec, L., A. J. Georges, G. Steenman, and P. M. V. Martin. 1989. Antibodies to human immunodeficiency virus in the semen of heterosexual men. J. Infect. Dis. 159:324-327.
8. Belshe, R. B., M. L. Clements, R. Dolin, B. S. Graham, J. McElrath, G. J. Gorse, D. Schwartz, M. C. Keefer, P. Wright, L. Corey, D. P. Bolognes, T. J. Matthews, D. M. Stablein, F. S. O'Brien, M. Eibl, F. Dorner, W. Koff, and the NIAID AIDS Vaccine Evaluation Group Network. 1993. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:1387-1395.
9. Biselli, R., L. D. Loomis, V. Bel Bono, D. S. Burke, R. R. Redfield, and D. L. Birx. 1994. Immunization of HIV-infected patients with rgp160: modulation of anti-rgp20 antibody spectrotype. J. Acquired Immune Defic. Syndr. 7:1016-1024.
10. Burnett, P. R., T. C. VanCott, V. R. Polonis, R. R. Redfield, and D. L. Birx. 1994. Serum IgA-mediatcd neutralization of HIV type 1. J. Immunol. 7:1-7.
11. Funkhouser, A., M. L. Clements, S. Slome, B. Clayman, and R. Viscidi. 1993. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-I and seronegative vaccine recipients. AIDS Res. Hum. Retroviruses 9:627-632.
12. Gorse, G. J., J. H. Rogers, J. E. Perry, F. K. Newman, S. E. Frey, G. B. Patel, R. B. Belshe, and the NIAID AIDS Vaccine Clinical Trials Network. 1995. HIV-1 recombinant gp160 vaccine-induced antibodies in serum and saliva. Vaccine 13:209-214.
13. Gorse, G. J., D. H. Schwartz, B. S. Graham, T. J. Matthews, D. M. Stablein, S. E. Frey, R. B. Belshe, M. L. Clements, P. F. Wright, M. Eibl, P. E. Fast, and the NIAID AIDS Vaccine Clinical Trials Network. 1994. Hiv-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin. Exp. Immunol. 98:178-184.
14. Leandersson, A. C., G. Bratt, M. Fredericksson, G. Gilljam, J. Hinkula, S. Nordlund, E. Sandstrom, and B. Wahren. 1996. Specific T-cell responses in HIV-1 infected patients immunized with a recombinant HIV-1 gp160 vaccine, abstr. Tu. A. 273, p. 222. In Abstracts of the XI International Conference on AIDS, July 1996, Vancouver, Canada.
15. Mannhalter, J. W., M. M. Eibl, B. Wahren, V. Blazevic, and F. D. Goebel for the European Multinational Immuno AIDS Vaccine Study Group. 1994. Lymphoproliferative responses in HIV-1-seronegative volunteers pre and post immunization with immuno rgp160, abstr. PB09305, p. 219. In Abstracts of the 10th International Conference on AIDS, August 1994, Yokohama, Japan.
16. McElrath, J., M. Keefer, P. Greenberg, R. Sposto, D. Chernoff, K. Steimer, and the NIAID AIDS Vaccine Evaluation Group. 1993. Evaluation of a nonglycosylated yeast-derived envelope vaccine on HIV-1-specific immunity in a randomized, blinded, controlled HIV-1 seropositive trial, abstr. PO-A28-0670, p. 245. In Abstracts of the IXth International Conference on AIDS, June 1993, Berlin, Germany.
17. Mestecky, J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7:265-276.
18. Mestecky, J., W. H. Kutteh, and S. Jackson. 1994. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immune deficiency virus. AIDS Res. Hum. Retroviruses 10(2):S11-S18.
19. Nielsen, K., P. Boyer, M. Dillon, D. Wafer, L. S. Wei, E. Garraty, R. E. Dickover, and Y. J. Bryson. 1996. Presence of human immunodeficiency virus (HIV) type 1 and HIV-1-specific antibodies in cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants. J. Infect. Dis. 173:1001-1004.
20. Redfield, R. R., D. L. Birx, N. Ketter, E. Gtramont, V. Polonis, C. Davis, J. F. Brundage, G. Smith, S. Johnson, A. Fowler, T. Wierzba, A. Shafferman, F. Volvovitz, C. Oster, D. S. Burke, and the Military Medical Consortium for Applied Retroviral Research. 1991. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N. Engl. J. Med. 324:1678-1684.
21. Redfield, R. R., and D. L. Birx. 1993. A hypothesis - postinfection vaccine therapy: a novel strategy for the prevention of HIV infection. Vaccines 93:49-56.
22. Schwartz, D., M. L. Clements, R. Belshe, G. Gorse, P. Wright, and B. Graham. 1993. Interim results of rgp160 vaccine trial in HIV+ volunteers, abstr. PO-A28-0668, p. 246. In Abstracts of the IXth International Conference on AIDS, June 1993. Berlin, Germany.
23. Straus, S. E., L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, S. F. Adair, and C. L. Dekker. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1468.
24. 3 CD4 T lymphocytes (AIDS Clinical Trials Group protocol 137). J. Infect. Dis. 173:1336-1346.
25. Vasudevachari, M. B., K. W. Uffelman, J. Kovacs, C. Yen, H. C. Lane, and N. P. Salzman. 1992. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-I gp 60. J. AIDS 5:818-821.
26. Viscidi, R., E. Ellerbeck, L. Garrison, K. Midthun, M. L. Clements, B. Clayman, B. Fernie, G. Smith, and the NIAID AIDS Vaccine Clinical Trials Network. 1990. Characterization of serum antibody responses to recombinant HIV-I gp160 vaccine by enzyme immunoassay. AIDS Res. Hum. Retroviruses 6:1251-1256.
27. Wolff, H., K. Mayer, G. Seage, J. Politch, C. R. Horsburgh, and D. Anderson. 1992. A comparison of HIV-1 antibody classes, titers, and specificities in paired semen and blood samples from HIV-1 seropositive men. J. Acquired Immune Defic. Syndr. 5:65-69.